Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Raised to Strong-Buy at Wall Street Zen

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

Bayer Aktiengesellschaft (OTCMKTS:BAYRY - Get Free Report) was upgraded by stock analysts at Wall Street Zen from a "buy" rating to a "strong-buy" rating in a report issued on Tuesday.

A number of other equities analysts have also commented on the company. Hsbc Global Res raised Bayer Aktiengesellschaft from a "hold" rating to a "strong-buy" rating in a research note on Wednesday, June 11th. The Goldman Sachs Group raised Bayer Aktiengesellschaft from a "hold" rating to a "strong-buy" rating in a research note on Thursday, June 5th. Finally, Kepler Capital Markets upgraded Bayer Aktiengesellschaft from a "hold" rating to a "buy" rating in a report on Wednesday, June 11th. One analyst has rated the stock with a hold rating, one has issued a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat.com, Bayer Aktiengesellschaft presently has an average rating of "Buy".

Bayer Aktiengesellschaft Stock Up 1.5%

BAYRY opened at $8.02 on Tuesday. The company has a debt-to-equity ratio of 1.07, a quick ratio of 0.79 and a current ratio of 1.25. The business has a 50 day moving average price of $7.87 and a 200 day moving average price of $6.83. The firm has a market cap of $31.52 billion, a P/E ratio of -8.27 and a beta of 0.91. Bayer Aktiengesellschaft has a twelve month low of $4.79 and a twelve month high of $8.65.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY - Get Free Report) last issued its quarterly earnings results on Wednesday, August 6th. The company reported $0.35 EPS for the quarter, topping the consensus estimate of $0.25 by $0.10. The company had revenue of $12.42 billion for the quarter, compared to the consensus estimate of $10.79 billion. Bayer Aktiengesellschaft had a positive return on equity of 15.48% and a negative net margin of 7.61%. Research analysts forecast that Bayer Aktiengesellschaft will post 1.31 EPS for the current year.

About Bayer Aktiengesellschaft

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.